Items tagged with Access
New TB drug making its way to India and Russia (post)
TOKYO -- With tuberculosis killing 1.67 million people every year, Otsuka Pharmaceutical is expediting deliveries of a new drug called Delamanid to India and other developing countries that are desperate for a cure.
Call for applications to serve on the Medicines Patent Pool’s TB Sub-Group of the Expert Advisory Group (post)
Non-remunerated position.
Three more hospitals in India get approval to administer bedaquiline (post)
Apart from KEM, Nair Hospital, Sion Hospital and Govandi’s Shatabdi Hospital will be able to administer bedaquiline to drug-resistant tuberculosis patients.
Essential drugs missing in India’s pharmacies (post)
[BANGALORE] India, dubbed as the ‘pharmacy of the developing world’ due to its vast generic drug exports, may not be doing enough to ensure availability of essential medicines in its domestic market, a new Indo-British study suggests.
Study: TRIPS flexibilities widely used by countries, contrary to reports (post)
Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities.
MSF welcomes Members of the European Parliament response to the US pharmaceutical pressure to stop EU action on high drug prices (post)
6 March 2018 — The Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), two US pharmaceutical lobby groups, have requested the US Trade Representative (USTR) to place the European Union (EU) on its 2018 Special 301 Report. This highly controversial Report by the USTR is an annual unilateral review of the enforcement of intellectual property rights (IPR) in other countries, and used as means to pressure countries to comply with the US demands for tougher IP rules that would eventually benefit the US pharmaceutical industry.
Extreme TB: Centre yet to push for cheaper versions of two crucial drugs (post)
Advanced patented medicines used to treat Drug Resistant Tuberculosis (DR-TB) are available to only about 1,000 patients out of the tens of thousands who need it, because the innovator-manufacturers are not ready to licence Indian drug-makers who can sell them at affordable prices.
WHO launches plan for cheaper TB drugs (post)
The World Health Organisation (WHO), on Tuesday (March 6), invited pharmaceutical companies around the world to submit proposals to manufacture affordable versions of newer medicines for treatment of drug-resistant tuberculosis (DR-TB).
Indian government negotiating with firms for better access to new TB drugs (post)
The government wants Johnson & Johnson and Mylan to provide treatment for multidrug-resistant TB patients as part of the Revised National Tuberculosis Control Programme.
J&J, Macleods in talks for license deal of TB drug (post)
Mumbai-based Macleods Pharmaceuticals and US drug giant Johnson & Johnson (J&J) are in talks for a voluntary license deal for the TB drug bedaquiline.
Page 32 of 83 · Total posts: 0
←First 31 32 33 Last→